Mitsubishi licenses Neurocrine movement disorders drug
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe has licensed the development and commercialization rights in Japan and other Asian markets for Neurocrine Biosciences' VMAT2 inhibitor, NBI-98854. Initially, Mitsubishi Tanabe will develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine will receive an initial payment of $30m and is eligible to receive up to $85m in additional milestone payments associated with the development and commercialization of NBI-98854 in Asia. It will also receive royalties on product sales in the relevant markets. The vesicular monoamine transporter 2 inhibitor product is already in Phase III tardive dyskinesia. It is designed to regulate levels of dopamine release during nerve communication but with fewer off-target side-effects. In addition to Japan, Mitsubishi Tanabe's territory also includes China, South Korea, Philippines, Indonesia, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.